Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa);Risultati preclinici e clinici con Gefitinib (ZD1839, Iressa) inibitore del recettore per il fattore di crescita epidermoidale

Minerva Medica

Volumn 95, Issue 3, 2004, Pages 233-241

  Di Cosimo, S ^a   Ferretti, G ^a   Milella, M ^a   Martinelli, E ^b   Alimonti, A ^a   Papaldo, P ^a   Carlini, P ^a   Fabi, A ^a   Matar, P ^c   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Laboratorio di Oncologia   (Spain)

Author keywords

Growth factors; Medical oncology; Neoplasms, Therapy

Indexed keywords

CYCLIN D1; CYCLIN E; CYTOCHROME P450 3A4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN KINASE B; PROTEIN P27; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; RAS PROTEIN; SOS PROTEIN; TRANSCRIPTION FACTOR FKHR; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; ENZYME INHIBITION; EYE TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NONHUMAN; RASH; REVIEW; SKIN TOXICITY; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; MICE; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 4744348435     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Cohen S, Carpenter G, King L Jr. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 1980;255:4834-42.
2. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
3. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984;307:521-7.
4. Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 1986;149:9-14.
5. Ward WH, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994;48:659-66.
6. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
7. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003;9:1274-83.
8. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-4.
9. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
10. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
11. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95.
12. Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, Ciardiello F, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13:65-72.
13. Swaisland H, Laight A, Stafford L, Jones H, Morris C, Dane A, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001;40:297-306.
14. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302.
15. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase-inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
16. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-25.
17. Nakagawa K, Yamamoto N, Kudoh S, Negoro S, Takeda K, Tamura T, et al. A phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumours. Proc Am Soc Clin Oncol 2000;19:711.
18. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.
19. Daneshmand M, Parolin DA, Hirte HW, Major P, Goss G, Stewart D, et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 2003;9:2457-64.
20. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002;21:28.
21. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. A phase II trial of ZD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) Proc Am Soc Clin Oncol 2002;21:292.
22. Giaccone G, Johnson DH, Manegold C, Scagliotti G, Rosell R, Wolf M, et al. A phase III clinical trial of ZD 1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol 2002;13(Suppl 5):2.
23. Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, et al. ZD 1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy naïve patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 2002;13(Suppl 5):128.
24. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor - are we missing the mark? Lancet 2003;362:62-4.